0000000000054404

AUTHOR

Simonetta Masieri

showing 4 related works from this author

Different skin prick test sensitization patterns do not influence the response to omalizumab in severe asthma

2017

Malemedicine.medical_specialtySevere asthmaSevere asthmaImmunologyEffectivenessOmalizumabOmalizumabSettore MED/10 - Malattie Dell'Apparato RespiratorioSeverity of Illness IndexmedicineHumansImmunology and AllergyAnti-Asthmatic AgentsSensitizationRetrospective StudiesSkin Testsbusiness.industryEffectiveneReal-lifeImmunoglobulin EEffectiveness; Omalizumab; Pollen sensitized; Real-life; Severe asthma; Immunology and Allergy; ImmunologyDermatologyAsthmaPollen sensitizedTest (assessment)Respiratory Function Testsmedicine.anatomical_structureTreatment Outcomeeffectiveness; omalizumab; pollen sensitized; real-life; severe asthmaFemaleImmunizationbusinessmedicine.drug
researchProduct

Mepolizumab effectiveness on small airway obstruction, corticosteroid sparing and maintenance therapy step-down in real life

2020

Background: Mepolizumab (MEP) has been recently introduced to treat severe eosinophilic asthma. Trials have demonstrated a significant effectiveness in this asthma phenotype. We evaluated MEP efficacy on lung function, symptoms, asthma exacerbations, biologic markers, steroid dependence and controller treatment level in real-life. Methods: We retrospectively analyzed 134 severe asthmatics (61 males; mean age 58.3 ± 11; mean FEV1%:72 ± 21), treated with MEP for at least 6 months (mean duration:10.9 ± 3.7 months). Results: FEV1% improved significantly after MEP. Mean FEF25-75 also increased from 37.4 ± 25.4% to 47.2 ± 27.2% (p < 0.0001). Mean baseline blood eosinophil level was 712 ± 731/μ…

MaleOmalizumabFEF(25-75)step-down0302 clinical medicineMaintenance therapyAdrenal Cortex HormonesSettore MED/10Pharmacology (medical)Anti-Asthmatic Agents030212 general & internal medicinesmall airwaysAsthma exacerbationsmepolizumabMiddle AgedAnesthesiaFEF25-75CorticosteroidDrug Therapy CombinationFemalemedicine.drugPulmonary and Respiratory Medicinesevere asthmamedicine.drug_classMepolizumab Severe asthma Real-life Small airways FEF25-75 Oral corticosteroids Step-down EffectiveneseffectivenessSettore MED/10 - Malattie Dell'Apparato Respiratoriooral corticosteroidsAntibodies Monoclonal HumanizedNO03 medical and health sciencesEffectiveness FEF 25-75 Mepolizumab Oral corticosteroids Real-life Severe asthma Small airways Step-downmedicineHumansIn real lifeFEFreal-lifeAgedRetrospective StudiesBiologic markerbusiness.industryEffectivenesBiochemistry (medical)Effectiveness; FEF; 25-75; Mepolizumab; Oral corticosteroids; Real-life; Severe asthma; Small airways; Step-downAirway obstructionmedicine.diseaseAsthmaBlood Cell Countrespiratory tract diseasesAirway ObstructionEosinophils030228 respiratory systemeffectiveness; FEF(25-75); mepolizumab; oral corticosteroids; real-life; severe asthma; small airways; step-down25-75businessMepolizumab
researchProduct

Factors reducing omalizumab response in severe asthma

2018

Background: Despite adding Omalizumab to conventional therapy, several severe asthmatics still show poor disease control. We investigated the factors that may affect a reduced Omalizumab response in a large population of severe asthmatics. Methods: 340 patients were retrospectively evaluated. FEV1%, FVC%, Asthma Control Test (ACT), fractional exhaled nitric oxide (FENO), possible step-downs/step-ups of concomitant therapies, exacerbations, disease control levels, ICS doses and SABA use, observed at the end of treatment, were considered as a response to Omalizumab. Results: Age was an independent risk factor for a reduced response concerning FEV1%, FVC%, ACT and for a lower asthma control. O…

MaleSevere asthmaDrug ResistanceComorbidityOmalizumabOmalizumabAdrenal Cortex HormoneComorbidities0302 clinical medicineRetrospective StudieAdrenal Cortex HormonesRisk FactorsForced Expiratory VolumeAge FactorNasal polypsAnti-Asthmatic Agents030212 general & internal medicineMultivariate AnalysiSmokingAge FactorsReal-lifeMiddle AgedTreatment OutcomeItalyFemaleComorbiditieHumanmedicine.drugAdultage; comorbidities; obesity; omalizumab; real-life; severe asthma; therapeutic response; internal medicinemedicine.medical_specialtyLogistic ModelTherapeutic responseSettore MED/10 - Malattie Dell'Apparato RespiratorioNitric Oxide03 medical and health sciencesFEV1/FVC ratioNasal PolypsAgeInternal medicineInternal MedicinemedicineAnti-Asthmatic AgentHumansObesityRisk factorRetrospective StudiesAsthmabusiness.industryRisk Factormedicine.diseaseComorbidityAsthmarespiratory tract diseasesLogistic Models030228 respiratory systemConcomitantMultivariate AnalysisExhaled nitric oxideNasal PolypAge; Comorbidities; Obesity; Omalizumab; Real-life; Severe asthma; Therapeutic responsebusinessEuropean Journal of Internal Medicine
researchProduct

Effects of omalizumab in severe asthmatics across ages: A real life Italian experience

2016

Background This retrospective study aimed at evaluating long-term effects of Omalizumab in elderly asthmatics in a real-life setting. Methods 105 consecutive severe asthmatics (GINA step 4–5; mean FEV1% predicted:66 ± 15.7) treated with Omalizumab for at least 1 year (treatment mean duration 35.1 ± 21.7 months) were divided into 3 groups according to their age at Omalizumab treatment onset: 18–39, 40–64 and ≥ 65 years. Results Comorbidities, number of overweight/obese subjects and patients with late-onset asthma were more frequent among older people. A similar reduction of inhaled corticosteroids dosage and SABA on-demand therapy was observed in all groups during Omalizumab treatment; a sim…

MaleSevere asthmaPediatricsComorbidityOmalizumabOmalizumabOverweightImmunoglobulin ESeverity of Illness IndexElderly0302 clinical medicineAdrenal Cortex HormonesForced Expiratory VolumeAge effectAnti-Asthmatic Agentsasthma allergy elderly omalizumab030212 general & internal medicineYoung adultbiologyReal-lifeAdrenergic beta-AgonistsMiddle AgedTreatment OutcomeItalyFemalemedicine.symptommedicine.drugAdultPulmonary and Respiratory Medicineage effect; elderly; omalizumab; real-life; severe asthmamedicine.medical_specialtyAdolescentSettore MED/10 - Malattie Dell'Apparato RespiratorioAntibodies Monoclonal HumanizedYoung Adult03 medical and health sciencesAge effect; Elderly; Omalizumab; Real-life; Severe asthma; Pulmonary and Respiratory MedicineAdministration InhalationSeverity of illnessmedicineHumansAgedRetrospective StudiesAsthmabusiness.industryRetrospective cohort studyImmunoglobulin Easthmaallergymedicine.diseaseComorbidity030228 respiratory systembiology.proteinbusinessRespiratory Medicine
researchProduct